Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06648850
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-17
Brief Title:
Clinical Study of DA-001 As a Treatment for Telogen Effluvium
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Study of DA-001 As a Treatment for Telogen Effluvium
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium
Detailed Description:
DA-001 is a topical alpha 1 agonist combined with a TAAR receptor agonist DA-001 was studies in a population of women that suffer from excessive shedding DA-001 demonstrated significant reduction in hair shedding
This study aims to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium
This study aims to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None